Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Carhart‐Harris, Robin; Roseman, Leor; Bolstridge, Mark; Demetriou, Lysia; Pannekoek, J. Nienke; Wall, Matthew B.; Tanner, Mark; Kaelen, Mendel; McGonigle, John; Murphy, Kevin; Leech, Robert; Curran, H. Valerie; Nutt, David

doi:10.1038/s41598-017-13282-7

articleScientific ReportsOct 9, 2017GOLD OA

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

RCRobin Carhart‐Harris LRLeor Roseman MBMark Bolstridge LDLysia Demetriou JNJ. Nienke Pannekoek

Imperial College London · Hammersmith Hospital · +3 more institutions

PubMed

Indexed incrossrefdoajpubmed

Abstract

Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the…

Citation impact

584

total citations

FWCI: 49.33
Percentile: 100%
References: 64

Citations per year

Authors

13

Topics & keywords

Topics

Keywords

Psilocybin
Functional magnetic resonance imaging
Default mode network
Prefrontal cortex
Neuroscience
Amygdala
Psychology
Cerebral blood flow

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.